Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC).
Caicun Zhou
Stock Ownership - Lilly; Roche
Honoraria - Lilly; Roche
Yi Long Wu
Honoraria - AstraZeneca; Lilly; Novartis; Pfizer; Roche; Sanofi
Xiaoqing Liu
No relevant relationships to disclose
Changli Wang
No relevant relationships to disclose
Gongyan Chen
No relevant relationships to disclose
Ji Feng Feng
No relevant relationships to disclose
Shucai Zhang
No relevant relationships to disclose
Jie Wang
No relevant relationships to disclose
Songwen Zhou
No relevant relationships to disclose
Shengxiang Ren
No relevant relationships to disclose
Shun Lu
Consultant or Advisory Role - AstraZeneca; Boehringer Ingelheim
Research Funding - AstraZeneca
Li Zhang
Consultant or Advisory Role - AstraZeneca; Boehringer Ingelheim; Novartis
Research Funding - AstraZeneca; Aventis; Hengrui; Lilly; MSD
Cheng-ping Hu
No relevant relationships to disclose
Yi Luo
No relevant relationships to disclose
Lei Chen
Consultant or Advisory Role - Roche
Research Funding - Roche
Ming Ye
No relevant relationships to disclose
Jianan Huang
No relevant relationships to disclose
Xiuyi Zhi
No relevant relationships to disclose
Yiping Zhang
No relevant relationships to disclose
Qingyu Xiu
No relevant relationships to disclose